2nd Metabolomics – Advances & Applications in Human Disease Conference May 21-22, 2015, Boston, MA

GTCbio is proud to present the 2nd Metabolomics – Advances & Applications in Human Disease Conference, which will be part of The Pan-Omics Summit and takes place May 21-22, 2015 in Boston, MA.

There is still significant human variability in metabolite identification for targets and pathways. These challenges affect the advancement in metabolomics, the use of biomarkers, and its application towards cancer, metabolic disorders, and neurodegenerative diseases. Join us for an event that presents new research and offers networking opportunities with the researchers and scientists who are working on developing clinical assays, connecting the metabolome and the genome, and establishing common quality standards for experimental data.

Sessions:
I. Advances in Metabolite Markers
II. Metabolite Identification – Targets and Pathways
III. Computational Approaches to Assessing the Metabolome
IV. Technological Advances in Metabolomics
Panel:
I. Clinical Applications of Metabolomics

http:://www.gtcbio.com/metabolomics?utm_source=metabolisam&utm_medium=eventlisting&utm_campaign=conferencelink

FMC 2015 – Frontiers in Medicinal Chemistry Antwerp, Belgium – September 14-16, 2015

The Frontiers in Medicinal Chemistry symposium is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry).

Frontiers 2015 will take place in Antwerp, Belgium, from September 14-16, 2015. It will be jointly organised by EFMC, ACS and the local Dutch and Belgian organisers: the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV, Belgium), the Société Royale de Chimie (SRC, Belgium), and the Section Medicinal Chemistry of the Royal Netherlands Chemical Society (KNCV, The Netherlands).

This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. It attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for Frontiers 2015 will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.

http://www.frontiers2015.org

Lyophilisation & Freeze Drying USA on 29-30 April 2015, Iselin, New Jersey

There’s a growing demand for lyophilised pharmaceutical products that are contributing to an increase in the adoption of lyophilisation equipment and the need for lyophilised biopharmaceuticals and other formulations in the pharmaceutical industry. This is contributing to the projected rise in investment, currently dominated by North America, which is expected to reach $4.80 billion in 2020. This rate of growth is a result of new biologics and biosimilars, enhancing the need for lyophilisation equipment and services.

The requirements governed by the FDA and supported by ISPE focus on improving patient safety and product quality – supporting the adoption of lyophilisation in pharmaceutical manufacturing, with the necessity to lyophilise APIs and various formulations such as antibodies, antiviral drugs, insulin, biosimilars, injections and other therapeutic proteins.

http://www.smi-online.co.uk/goto/2015lyophilisationusa45.asp

Pharmacovigilance, Drug Safety & Risk Management 11-12 May 2015, London UK

The expansive field of drug surveillance has increased the complexity of problems across the board in relation to PV auditing and meeting the standard requirements. Companies continue to face challenges of understanding the key considerations when presenting to auditors and knowing how to adequately adapt to different regulatory environments and changes. Moreover, clarifying individual roles within the PV system is paramount to setting out clear goals and meeting regulatory expectations.

For any company looking to globalize their business, the governance of reporting adverse drug events by different centralized authorities, along with heterogeneous terminologies and competing priorities has created greater uncertainties and barriers to enter new markets. The daunting task of complying with multiple regulations also heightens the danger of unrealistic expectations as well as mounting costs and time that will have long-term implications on investment.
Therefore, the importance of a centralised database has never been more vital to employ knowledge sharing and product awareness.

Join SMi in tackling these issues: 2015 will bring a focus on drug surveillance and signal detection; analysis and prevention of adverse drug reactions with MedDRA, industry experiences and global regulatory coverage of developments. Furthermore, we will cover Eudravigilance, and the growing trend of outsourcing Pharmacovigilance, as well as navigate through the challenges of compiling PSUR’s and frequent safety reports and how to adapt better to regulatory updates by preparing key areas that will be most impacted.

http://www.smi-online.co.uk/goto/2015pharmacovigilance33.asp

Stem Cells in Drug Discovery 2015, 2-3 June 2015, Cambridge, UK

SELECTBIO is pleased to announce, that due to popular demand we will be hosting a workshop on Stem Cells in Drug Discovery at Buckingham House, Murray Edwards College in Cambridge, UK.

At the workshop you will hear from leaders in stem cell research, working towards models for drug testing; previously thought to be impossible, and professionals screening for efficacy and toxicity of experimental compounds using iPS cell lines, also those responsible for developing the techniques and technologies that are enabling them to do so.

Keynote Speakers:

– Stephen Minger
Global Director, GE Healthcare

– Wei Zheng
Group Leader, National Institute of Health

Agenda Topics: